Nxera Pharma Co (Nxera Pharma Co) Gross-Profit-to-Asset % : 14.65% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Nxera Pharma Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Nxera Pharma Co's annualized Gross Profit for the quarter that ended in Dec. 2023 was $153.96 Mil. Nxera Pharma Co's average Total Assets over the quarter that ended in Dec. 2023 was $1,051.29 Mil. Therefore, Nxera Pharma Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 14.65%.

Nxera Pharma Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Nxera Pharma Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Gross-Profit-to-Asset % Chart

Nxera Pharma Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

13.85

12.40

18.56

13.66

7.34

Nxera Pharma Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															28.53	3.45	4.11	6.82	14.65

Competitive Comparison of Nxera Pharma Co's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Nxera Pharma Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nxera Pharma Co's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Gross-Profit-to-Asset % falls into.

Nxera Pharma Co Gross-Profit-to-Asset % Calculation

Nxera Pharma Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	67.12	/	( (736.887	+	1091.793)	/ 2 )
	=	67.12	/	914.34
	=	7.34 %

Nxera Pharma Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	153.964	/	( (1010.782	+	1091.793)	/ 2 )
	=	153.964	/	1051.2875
	=	14.65 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Nxera Pharma Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nxera Pharma Co (Nxera Pharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (OTCPK:SOLTF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

4565:Japan JSS:Germany

Address

2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083

Website

http://www.sosei.com

Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.